YAVNE, Israel, May 30, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting BexPharm Korea Co. Ltd. exclusive rights to market and distribute NexoBrid® in South Korea for the treatment of severe burns upon receipt of regulatory approval. An estimated 10,000 patients with severe burns are hospitalized every year in South Korea and primarily are treated at approximately 10 burn centers.
Help employers find you! Check out all the jobs and post your resume.
